title: [Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
abstract: OBJECTIVE
  To evaluateclinical features, treatment and outcomes of patients diagnosed with primary breast diffuse large B-cell lymphoma（DLBCL）.
  
  
  METHODS
  Clinical data were analyzed for all patients diagnosed with primary breast DLBCL（n=21）. Kaplan-Meier method was used to estimate 5- year overall survival（OS）rate, and the difference was compared by Log- rank test.
  
  
  RESULTS
  The 21 cases of patients with primary breast DLBCL were all female with median age at diagnosis as 48 years （range 21-64 years）. 13 patients had International Prognostic Index（IPI）of 0, 6 IPI 1, and 2 IPI 2. The 5- year OS rates of CHOP/R- CHOP and R±DICE after R±EPOCH groups were 40.0% and 72.2% , respectively（P=0.035）. The central nervous system relapse rate of CHOP/R-CHOP and R±DICE after R± EPOCH groups were 16.7% and 6.7%（P=0.500）, respectively. The 5- year OS rates of patients with primary breast DLBCL staging Ⅱ E-Ⅲ E and Ⅰ E were 21.4% and 83.3% , respectively（P=0.025）.
  
  
  CONCLUSIONS
  Primary breast DLBCL was rare. The patients of primary breast DLBCL with chemotherapy regimen of R±DICE after R±EPOCH might have a better prognosis and lower relapse rate of central nervous system; the primary breast DLBCL patients staging ⅡE-ⅢE might have a poor prognosis.
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Yufu
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Jianwei
authors.initials: J
authors.lastname: Du
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Dong
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Gangping
authors.initials: G
authors.lastname: Li
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Xudong
authors.initials: X
authors.lastname: Wei
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, He'nan Cancer Hospital, Zhengzhou 450008, China.
authors.forename: Yongping
authors.initials: Y
authors.lastname: Song
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D002681:China; D002945:Cisplatin; D003520:Cyclophosphamide; D003907:Dexamethasone; D004317:Doxorubicin; D005047:Etoposide; D005260:Female; D006801:Humans; D007069:Ifosfamide; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D007069:Ifosfamide; D011241:Prednisone